The present disclosure is directed at methods and apparatus to evaluate and monitor healing progress of wound and/or to generate data to modify or identify a treatment protocol. Fluid exudate removed from the wound by a negative pressure therapy device may now be analyzed to identify the progress of wound healing, such as whether healing is progressing in a positive manner or experiencing one or more impediments. The fluid exudates may be specifically analyzed for one or more analytes indicative of one or more of the biochemical reactions that may occur during wound recovery. In addition, one may separately utilize optical sensors integrated into a dressing enclosure, optionally in those dressings employed in a negative pressure therapy device. Such optical sensors may then illuminate the wound and collect information regarding the wound via a light scattering type response.
|
1. An apparatus to evaluate and monitor healing progress of a wound and to generate data to modify or identify a treatment protocol comprising:
a dressing enclosure for administering reduced pressure treatment to a wound, wherein the enclosure is configured to cover the wound and to maintain reduced pressure at the wound location;
a device capable of supplying reduced pressure;
a microfluidic device including a closed-channel continuous flow system connected between said dressing enclosure for said wound and said device capable of supplying reduced pressure to withdraw fluid exudates containing one or more analytes from said wound wherein said microfluidic device includes first and second compartments wherein in said first compartment an analyte that is one of said one or more analytes binds with one or more labeled antibodies or aptamers and in a second compartment the bound analyte is detected; and
a sensor in said second compartment of said microfluidic device capable of analyzing said fluid exudates for one or more analytes indicative of said progress of wound healing and said analyzing of said fluid exudates is done continuously without disruption of said reduced pressure at said wound location and providing real time analysis of wound healing and providing real-time treatment protocol adjustments.
13. A method to evaluate and monitor healing progress of a wound via analysis of wound fluid exudate comprising:
locating a dressing enclosure for administering reduced pressure treatment to a wound at a wound location, wherein said enclosure is configured to cover said wound and to maintain reduced pressure at the site of the wound;
supplying a device that provides reduced pressure to said dressing enclosure;
locating a microfluidic device including a closed-channel continuous flow system between said dressing enclosure for said wound and said device capable of supplying reduced pressure;
withdrawing fluid exudate from said wound containing one or more analytes wherein said microfluidic device includes first and second compartments wherein in said first compartment an analyte that is one of said one or more analytes binds with one or more labeled antibodies or aptamers and in a second compartment the bound analyte is detected;
supplying a sensor in said second compartment of said microfluidic device capable of analyzing said fluid exudates for one or more analytes indicative of the progress of said wound healing and said analyzing of said fluid exudates is done continuously without disruption of said reduced pressure at said wound location; and
identifying one or more of said analytes and providing real time analysis of wound healing and providing real-time treatment protocol adjustments.
2. The apparatus of
3. The apparatus of
4. The apparatus of
5. The apparatus of
6. The apparatus of
7. The apparatus of
8. The apparatus of
9. The apparatus of
10. The apparatus of
11. The apparatus of
12. The apparatus of
|
|||||||||||||||||||||||||||
The present invention relates to methods and apparatus for assessing medical progress. More specifically, the present invention relates to methods and apparatus that may be employed to evaluate and monitor the progress of healing in response to a particular dressing or treatment protocol as well as generating data to modify or identify an alternative protocol.
Physicians and other medical practitioners often desire a need to evaluate how a particular wound is progressing under a given treatment protocol. When assessing healing, in routine practice, it is often the case that a determination may be visually made on experience and qualitative considerations. In addition, for many wound dressings, it is not possible to evaluate undesirable conditions as they occur, and one may wait several days until the dressing may be removed to identify a given undesirable condition. Accordingly, there is a need to develop more quantitative techniques that may more efficiently identify and predict wound healing progress.
In a first exemplary embodiment, the present disclosure is directed at an apparatus to evaluate and monitor healing progress of wound and/or to generate data to modify or identify a treatment protocol. The apparatus comprises a dressing enclosure for administering reduced pressure treatment to a wound, wherein the enclosure is configured to cover the wound and to maintain reduced pressure at the wound location. One may then supply a device capable of supplying reduced pressure and a fluid trap connected between the dressing enclosure for the wound and the device capable of supplying reduced pressure to withdraw fluid exudate from said wound. A sensor may then be provided that is capable of analyzing the fluid exudate for one or more analytes indicative of the progress of wound healing.
In another exemplary embodiment, the present disclosure is again directed at an apparatus to evaluate and monitor healing progress of wound and/or to generate data to modify or identify a treatment protocol. The apparatus comprises a dressing enclosure for administering reduced pressure treatment to a wound, wherein the enclosure is configured to cover the wound and to maintain reduced pressure at the wound location. One may then supply a device capable of supplying reduced pressure and a microfluidic device connected between the dressing enclosure for the wound and the device capable of supplying reduced pressure to withdraw fluid exudate from said wound. A sensor may then be provided in the microfluidic device that is capable of analyzing the fluid exudate for one or more analytes indicative of the progress of wound healing.
In another exemplary embodiment, the present invention is directed to an apparatus to evaluate and monitor healing progress of a wound comprising a dressing enclosure, wherein the enclosure is configured to cover the wound. One may then supply an optical sensor in the dressing enclosure, wherein the optical sensor is configured to provide varying wavelengths of light to said wound location and to sense and report any corresponding light scattering. Such an optical sensor may optionally be used with any of the NPTD sensor configurations disclosed herein.
The present disclosure also relates to a method to evaluate and monitor healing progress of wound and/or to generate data to modify or identify a treatment protocol. The method includes locating a dressing enclosure for administering reduced pressure treatment to a wound at a wound location, wherein the enclosure is configured to cover the wound and to maintain reduced pressure at the site of the wound. This may then be followed by supplying a device that provides reduced pressure to the dressing enclosure and locating a fluid trap connected between the dressing enclosure for the wound and the device capable of supplying reduced pressure. One may then withdraw fluid exudate from the wound and supply a sensor capable of analyzing the fluid exudates for one or more analytes indicative of the progress of the wound healing followed by identification of one or more of such analytes.
In addition, the present disclosure also relates to a method to evaluate and monitor healing progress of wound and/or to generate data to modify or identify a treatment protocol. The method includes locating a dressing enclosure for administering reduced pressure treatment to a wound at a wound location, wherein the enclosure is configured to cover the wound and to maintain reduced pressure at the site of the wound. This may then be followed by supplying a device that provides reduced pressure to said dressing enclosure and locating a microfluidic device between the dressing enclosure for the wound and the device capable of supplying reduced pressure. One may then withdraw fluid exudate from the wound and supplying a sensor within said microfluidic device that is capable of analyzing said fluid exudate for one or more analytes indicative of the progress of said wound healing followed by identification of one or more of said analytes.
The above-mentioned and other features of this disclosure, and the manner of attaining them, may become more apparent and better understood by reference to the following description of embodiments described herein taken in conjunction with the accompanying drawings, wherein:
A first aspect of the present invention relates to sampling fluid produced by or in contact with a wound, wherein the sampling may be configured to be continuous thereby providing real-time evaluation of a given wound-treatment protocol. A wound herein may be understood as that situation where skin may be torn, cut or punctured (e.g. an open wound). The wound may also be an internal wound where skin may be cut to insert an internal dressing. Wounds herein may also include both acute and chronic wounds, wherein an acute wound is a wound that is the result of injuries that disrupt the tissue and a chronic wound are those that may be caused by a relatively slow process that leads to tissue damage (e.g., pressure, venous an diabetic ulcers).
More specifically, fluid may be extracted from a wound, which may be facilitated by the use of a negative pressure therapy device (NPTD). A NPTD may be understood as a device that may apply sub-atmospheric pressure (e.g. <760 mm Hg) to a wound location. The wound may be partially or fully covered to facilitate the development of negative pressure at a desired region. Various types of relatively resilient foam surface dressing are typically sealed within an adhesive drape to assist in the formation of vacuum at the wound site.
The use of the NPTD typically provides a variety of advancements in wound management. Among these may include active removal of extra-cellular debris, decrease in peri-wound edema, thereby increasing wound profusion and improving nutrition. In addition, the use of NPTD may also provide wound contracture, decreased bacterial colonization, increased rates of granulation tissue formation and epithealization and stimulation of mitosis and angiogensis.
Attention is therefore directed to
For example, when it is desired to evaluate the fluid for the presence or absence of a particular target molecule, bacteria, biomarker (any kind of molecule that may indicate the existence, past or present, of living organisms) or tissue growth factors (e.g. TGF-beta) the negative pressure may be selectively increased or applied for a chosen period of time to secure a fresh sample for analysis. In addition, according to such protocol, it may be appreciated that the extracted wound fluids may provide an indication of target molecules and/or bacteria within a given soft tissue gradient.
For purposes of creating suction within the system the enclosure 12 is connected to a vacuum system generally designated at 16 which provides a source of suction or reduced pressure at the wound site. Valves 13 may be employed to selectively control the application of the negative pressure. A fluid trap/canister is shown generally at 14 that may be connected between the vacuum systems 16 which enable one to collect fluid exudates from the wound for temporary storage or analysis. The fluid trap may optionally contain a sensor 14A integrated in the canister or the sensor may be positioned within the illustrated flow lines 15 or in parallel with such lines or positioned within a microfluidic device 20. Accordingly, one or a plurality of sensors may be used in any particular desired configuration. The sensor(s) may be connected to a computer 14C or other data processing unit. The computer 14C may be integrated within the NPTD such that sensor readings could be used to adjust on-going therapy profiles. Predetermined amounts of suction or reduced pressure may be produced by vacuum system 16 as inputted from the controller 18. The fluid trap may include a float-valve assembly (not shown) which may seal off the suction of the fluid trap when the quantity of fluid in the trap 14 exceeds a predetermined level.
The microfluidic device 20 is specifically capable of providing a closed-channel continuous flow system which contains and manipulates a relatively small amount of fluid within a micro-channel structure. Such micro-channel structure may be produced by micro-processing technology such as photolithography. The device may also be manufactured by metal etching, deposition and bonding, soft lithography, thick-film and stereolithography as well as by relatively fast replicating methods such as electroplating, injection molding and embossing. The flow passages may therefore have a width and depth of 1 μm to 500 μm which may be configured to offer a flow rate at a sensor location of 1 μL/min to 100 μL/min. The microfluidic device 20 may also contain a sensor for sampling of the fluid under consideration.
The sensor herein, which may be utilized within the canister, the flow lines, and/or within the microfluid chip, may be broadly understood as any device that provides analysis of the fluid exuded from or in contact with the wound, which sensor provides information regarding the progress of wound healing. Reference to the progress of wound healing may be understood as determining whether wound healing is progressing in a positive manner towards an orderly healing cascade and/or whether the healing progress is experiencing one or more impediments, such as an increase in bacterial burden which may occur when wounds become critically colonized or infected where organisms may be present at levels of greater than 105 CFU (colony forming units) per gram of tissue. Furthermore, as noted above, the sensor, in combination with computer 14C may now provide the ability for the therapy protocol to be adjusted. Under a negative pressure therapy protocol, the amount or cycling of the negative pressure could be altered. Additionally, antibiotics could be instilled into the wound to address bacterial infections. A lack of wound healing can also suggest the need for additional debridement. Typically, these issues are not known until after the treatment protocol has been completed, which can result in further damage to the wound.
The sensor may therefore rely upon the presence or lack of presence of a given analyte within the exuded fluid or biochemical reactions between specific analytes within such fluids present within the sensor environment (e.g. within the canister 14) that provide a color output, electrical output or other quantifiable reaction whose rate or extent is proportional to the concentration of those analytes that are desired for analysis. Accordingly, the present disclosure allows one, in conjunction with the NPTD, to continuously measure the chemical entities (e.g. analytes) present within wound fluid and for reporting these concentrations and ratios between the various chemical entities during the healing process.
As now may be appreciated, to the extent that it is desirable to continuously monitor a selected analyte within the fluid exudates, one may generally employ a device known as a colorimeter, which may be understood as a device that measures the absorbance of particular wavelengths of light by a specific solution. This may then be utilized to identify the particular concentration of a selected analyte in solution wherein the concentration of the analyte in solution is proportional to the absorbance. A critical determination may then be made for predicting the course and probability of successful healing within an interval acceptable to patients and their care providers, so that the most appropriate and cost-effective treatment may be selected.
For example, one may elect to specifically monitor oxygen levels within a fluid exudate and/or fluid pH. One may therefore rely upon colorimetric and/or fluorescence change along with LED excitation and an optical detector. In addition, one may include oxygen and/or pH sensitive chromophores in the exudates fluids, which may be introduced within the canister and/or fluid flow path to improve detection and resolution. In the specific situation of oxygen detection, one may utilize an oxygen sensitive chromophore such as tris(2,2-bipyridyl)dichlororuthenium(II) hexahydrate [Ru(Bpy)]. It is also contemplated herein that one may utilize a phosphorescent dye that is mixed within the fluid exudate and excited using appropriate illumination, such that the phosphorescence lifetime and intensity become indicators of oxygen concentration in the wound environment. In addition, any one or more chromophores identified herein may optionally be encapsulated in microporous beads, having a size (largest linear dimension) of 1.0 nm to 1.0 μm.
Examples of pH chromophores that may be introduced in the exudate fluid may include pH sensitive dyes that exhibit a color shift over a desired pH range. For example, Bromocresol purple changes from yellow to violet between the pHs of 5.2 and 6.8 and Alizarin turns from yellow to red between pHs of 5.6 and 7.1. Other pH indicators may include Bromothymol Blue, Neutral Red, Congo Red, Thymol Blue, etc.
One may also now conveniently and continuously monitor the presence of analytes such as pro-inflammatory cytokines and/or proteases within the wound fluid. Cytokines reference signaling molecules and a relatively large and diverse family of polypeptide regulators of host responses to infection, immune response, inflammation and trauma. Some cytokines act to make disease worse (proinflammatory) whereas others serve to reduce inflammation and promote healing (anti-inflammatory). Interluekin (IL)-1 and (IL)-10 are examples of proinflammatory cytokines and anti-inflammatory cytokines, respectively. Protease may be understood as any enzyme that conducts proteolysis, that is, begins protein catabolism by hydrolysis of the peptide bonds that link amino acids together in polypeptide chains, which form the molecule of a given protein.
With attention again to
The labeled antibodies or aptamers may themselves include tags that are responsive to sensor 14A. For examples, the tags may be responsive to light energy (e.g. fluorescent tags) or provide electrochemical activity for electrochemical detection. The microfluidic device 20 may include two compartments, 20A and 20B. In the first compartment 20A, the binding of the target analyte may take place with a selected antibody or aptamer. The exudate fluid containing the bound analyte may then be introduced into the second compartment 20B where the bound analytes may be detected. The advantage of utilizing the microfluid device 20 in combination with the NPTD is realized in that only a relatively small amount of antibody or aptamer may be used and as noted herein, the analysis of a selected analyte may be done continuously without disruption of the negative pressure treatment protocol.
As may now also be appreciated, by utilizing and introducing more than one labeled antibody or aptamer, more than one targeted analyte may be identified within the fluid extracted from a wound. For example, it is contemplated herein that one may identify portions of the basic metabolic panel (BMP), which as applied to wound fluid, includes the identification of glucose, calcium, sodium, potassium, carbon dioxide, and/or chloride. In addition, the targeted analyte may include a matrix metallo proteinase, which may be understood as any of a group of endopeptidases that hydrolyze proteins of the extracellular matrix. Finally, the targeted analyte may include bone morphogenic proteins.
In a related embodiment, the present disclosure also relates to the incorporation of an array of optical sensors on the surface of a wound dressing, that may optionally involve a NPTD and negative pressure treatment protocol. Such placement of the optical sensors would then allow for imaging of the wound site which may then provide for the ability to monitor one or more of the following parameters: 1. wound bed circulation; 2. formation of scar tissue; 3. debridement of necrotic tissue; 4. state of wound closure and the amount of epithelialization.
Accordingly, one may incorporate an optical sensor within a wound dressing at the wound location, integrated into the dressing and/or its enclosure, which optical sensor may provide varying wavelengths to monitor selected wound healing events, including fibrosis, or wound biological conditions and/or delivery of drugs, etc. For example, as shown again in
One may also now selectively vary the wavelength of light reflected within the wound site such that at wavelengths within the light range of 350 nm-700 nm, and more specifically, at wavelengths of less than or equal to 450 nm (e.g., 350 nm to 450 nm) one may generate scattering of epithelial surface tissue. That is, one may monitor the wound site up to a thickness of about 5.0 mm. Accordingly, one may monitor the formation of fibrin clots, fibroblast development, and collagen incorporation. By contrast, wavelengths of equal to or greater than 600 nm (e.g. 600 nm to 1400 nm) will tend to supply information of underlying tissue properties (e.g., collagen fiber structure, changes such as increase or decrease in blood flow circulation, oxygenation level of the blood supply, etc.). Reference to collagen fiber structure may be understood as reference to a determination of structure at the monomeric level (individual collagen molecules) and/or at the aggregate level (how the amino acids may be arranged or packing structure). That is, in the case of such wavelengths, one may monitor for the indicated parameters up to a thickness of about 3.0 cm. The sensor 12A may specifically include excitation and collection optical fibers integrated in the dressing where the scattering information may then be collected and forwarded to computer device 14C.
In addition, it is contemplated herein that the structural characteristics of the wound may be monitored using reflectance imaging. Structural characteristics may include deposition of collagen fibers, regeneration of stromal (dermal) and epidermal section and fibrosis and development of scars. Accordingly, changes in biochemical structure of tissue will change the reflectance properties, which may now be appropriately monitored.
Furthermore, the optical sensor may be useful in the identification of bacterial biofilm formation (an aggregation of microorganisms on a substrate). This may be based on unique autofluorescence properties of certain bacteria's and biofilms. Such fluorescence may result when cells are excited by either UV radiation (10 nm to 400 nm) or light at wavelengths of 400 nm to 700 nm. Accordingly, the present invention contemplates the use of a fluorescence response at wavelengths of 10 nm to 700 nm.
In addition, as shown in
Although the foregoing invention has been described in some detail by way of illustration and example for purpose of clarity and understanding, it will be apparent to those skilled in the art that certain changes and modifications will be practiced. Therefore, the description and examples should not be construed as limiting the scope of the invention, which is delineated by the appended claims
Hanson, Heather S., Nitin, Nitin
| Patent | Priority | Assignee | Title |
| Patent | Priority | Assignee | Title |
| 6080574, | May 10 1994 | Becton, Dickinson and Company | Composite optical blood culture sensor |
| 6162646, | Apr 01 1997 | William H., Webster | Urine pH indicator system and associated methods |
| 7216651, | Nov 14 1991 | WAKE FOREST UNIVERSITY HEALTH SCIENCES | Wound treatment employing reduced pressure |
| 7327459, | Dec 30 2003 | Samsung Electronics Co., Ltd. | Fluorescence detector for detecting microfluid |
| 7485266, | Aug 06 2004 | Hitachi, LTD | Micro fluid chip |
| 7534240, | Apr 02 1999 | Kinetic Concepts, Inc | Negative pressure wound therapy system with provision for introduction of an agent |
| 20040038292, | |||
| 20050140978, | |||
| 20080045807, | |||
| 20080071161, | |||
| 20080077091, | |||
| 20080132819, | |||
| 20080140029, | |||
| 20080271804, | |||
| 20100217172, | |||
| 20110130712, | |||
| WO2005078439, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Jul 14 2009 | Southwest Research Institute | (assignment on the face of the patent) | / | |||
| Aug 18 2009 | HANSON, HEATHER S | Southwest Research Institute | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 023308 | /0793 | |
| Aug 20 2009 | NITIN, NITIN | Southwest Research Institute | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 023308 | /0793 |
| Date | Maintenance Fee Events |
| Aug 15 2013 | ASPN: Payor Number Assigned. |
| Mar 02 2017 | M2551: Payment of Maintenance Fee, 4th Yr, Small Entity. |
| Mar 03 2021 | M2552: Payment of Maintenance Fee, 8th Yr, Small Entity. |
| Date | Maintenance Schedule |
| Sep 17 2016 | 4 years fee payment window open |
| Mar 17 2017 | 6 months grace period start (w surcharge) |
| Sep 17 2017 | patent expiry (for year 4) |
| Sep 17 2019 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Sep 17 2020 | 8 years fee payment window open |
| Mar 17 2021 | 6 months grace period start (w surcharge) |
| Sep 17 2021 | patent expiry (for year 8) |
| Sep 17 2023 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Sep 17 2024 | 12 years fee payment window open |
| Mar 17 2025 | 6 months grace period start (w surcharge) |
| Sep 17 2025 | patent expiry (for year 12) |
| Sep 17 2027 | 2 years to revive unintentionally abandoned end. (for year 12) |